---
title: "Abbisko's anti-tumor targeted drug Bejimai Phase III study results published in The Lancet"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278299390.md"
description: "The results of the Phase III MANEUVER study of the anti-tumor targeted drug Abemaciclib (ABSK021) by ABBISKO-B were published in The Lancet on March 5th. The study included 94 subjects across more than 30 clinical centers worldwide, demonstrating significant efficacy of Abemaciclib in treating patients with tenosynovial giant cell tumors (TGCT) and showing good safety characteristics, indicating its potential in the treatment of related indications"
datetime: "2026-03-09T01:09:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278299390.md)
  - [en](https://longbridge.com/en/news/278299390.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278299390.md)
---

# Abbisko's anti-tumor targeted drug Bejimai Phase III study results published in The Lancet

Abbisko-B (02256.HK) officially published the results of its self-developed novel, oral, highly selective, and efficient small molecule CSF-1R inhibitor, Beijiemai (ABSK021, Pimitinib Hydrochloride Capsules), in the international medical journal The Lancet on March 5 (Western European time).

The company stated that the MANEUVER study included 94 subjects across more than 30 clinical centers worldwide, with over half of the patients being from outside China. The results showed that Beijiemai achieved significant efficacy in treating patients with tenosynovial giant cell tumors (TGCT) and overall demonstrated good safety characteristics, indicating its potential in the treatment of related indications

### Related Stocks

- [562050.CN](https://longbridge.com/en/quote/562050.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159570.CN](https://longbridge.com/en/quote/159570.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [520500.CN](https://longbridge.com/en/quote/520500.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [02256.HK](https://longbridge.com/en/quote/02256.HK.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)

## Related News & Research

- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Wuxi AppTec to Raise Around $1 Billion Through Zero Coupon Convertible Bonds](https://longbridge.com/en/news/286487023.md)
- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)
- [FDA approves FoundationOne CDx as TEPMETKO companion diagnostic in NSCLC](https://longbridge.com/en/news/287246470.md)